/ Pre-IPO Risk Index / Ro (Roman / Rory / Zero)

Ro (Roman / Rory / Zero)

Healthcare (Consumer Telehealth) · Pre-IPO · $7B (Q1 2022; secondary 2024 reset)
C+

Mixed (C+) — Round Z Pre-IPO Risk Grade

Ro operates a consumer telehealth platform across men's health (Roman), women's health (Rory), weight loss (Zero/GLP-1), and other vertical conditions. The 2024 GLP-1 weight-loss boom produced material revenue growth but also intense competitive pressure and regulatory scrutiny.

62
Composite / 100
/ Subscore Breakdown · 5 Dimensions

Where this grade comes from.

Governance Risk
C+
Valuation Methodology
C
Secondary Liquidity
C+
Financial Disclosure
C
Exit Probability
C+
/ Public-Record Events

Key risk events & disclosures.

  • GLP-1 weight-loss product launch 2023 — material revenue growth
  • FDA + FTC scrutiny of compounded GLP-1 marketing 2024
  • $7B 2022 valuation; secondary trades at meaningful discount
  • Multiple consumer telehealth competitive pressures (Hims, Eli Lilly direct)

/ Best for

Investors who can price the GLP-1 regulatory outcome and have conviction on consumer-telehealth post-reset economics.

/ Watch out for

FDA crackdown on compounded GLP-1 marketing is the largest near-term revenue risk.